Moneycontrol Bureau
Suven Life Sciences shares rallied more than 5 percent intraday Tuesday after getting patents from Europe and Israel.
"...announces that the grant of one product patent from Europe and one product patent from Israel corresponding to the new chemical entities for the treatment of disorders associated with neurodegenerative diseases," the healthcare company said in its filing.
These patents are valid through 2030 and 2029 respectively. These are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like alzheimer's disease, attention deficient hyperactivity disorder (ADHD), huntington’s disease, major depressive disorder, parkinson and schizophrenia.
With these new patents, Suven has a total of 23 granted patents from Europe and 12 granted patents from Israel.
"These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II," the company said.
At 10:27 hours IST, the scrip of Suven Life Sciences was quoting at Rs 199.20, up Rs 5.05, or 2.60 percent on the BSE.Posted by Sunil Shankar Matkar
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
